Who may be eligible for the The Genotype and Phenotype of Lymphangioleiomyomatosis trial?

Inclusion Criteria: * age ≥ 18 y/o * Patient with Chest CT showed cystic lung disease, suspected Lymphangioleiomyomatosis Exclusion Criteria: * age \< 18 y/o

ClinicalTrials.gov record NCT06405997

The Genotype and Phenotype of Lymphangioleiomyomatosis

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

The Genotype and Phenotype of Lymphangioleiomyomatosis

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.The registry record was last updated on May 9, 2024, about 2 years ago, so the status shown may be out of date. The study team or the registry can confirm.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Age18 years old and older

SexAll

LocationTaiwan

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This prospective observational study collects genetic and clinical information from adults with cystic lung disease suspected to be lymphangioleiomyomatosis (LAM). Its goal is to distinguish sporadic LAM from LAM associated with tuberous sclerosis complex (TSC) by comparing genetic findings and clinical features.

What it is studying. The study is testing how the genotype (genetic findings) and phenotype (clinical features) compare between sporadic LAM and TSC-associated LAM.

What the researchers hope to learn. To describe and compare the genetic (genotype) and clinical (phenotype) characteristics of sporadic versus TSC-associated LAM.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This study aims to differentiate between sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex-associated Lymphangioleiomyomatosis.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

age ≥ 18 y/o
Patient with Chest CT showed cystic lung disease, suspected Lymphangioleiomyomatosis

Exclusion criteria

age < 18 y/o

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

The registry record gives limited procedure details. It states the study will collect information about participants' genotype and phenotype (primary outcome) with assessment at one month, but does not list specific tests, samples, visit schedules, or other activities. The record does not provide further details about what participants will be asked to do.

How the study is structured. A prospective observational cohort study: researchers follow participants forward in time and collect clinical and genetic information. No experimental treatment is assigned as part of the study.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in Taiwan. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on lymphangioleiomyomatosis

Clinical trials10 trials listed for lymphangioleiomyomatosisEvery trial the registry lists for lymphangioleiomyomatosis, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in lymphangioleiomyomatosis researchLatest monthly update: September 2026. Includes: Pleural fluid drainage. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: May 10, 2024 (estimated)
Primary completion: Jul 31, 2027 (estimated)
Study completion: Jul 31, 2027 (estimated)
Target enrollment: 100 participants (estimated)
Last updated on registry: May 9, 2024
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: National Taiwan University Hospital

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Yao-Wen Kuo 📞 0972-651-821 ✉ kyw@ntu.edu.tw

Participating sites (1)

National Taiwan University HospitalRecruiting
Taipei · Taiwan
- Yao-Wen Kuo, MD · 0972-651-821 · kyw@ntu.edu.tw

Terms used on this page · explanations by MedicalUpdates.ai

CT: An X-ray scan that builds detailed cross-section images of the body. 'High-resolution' CT (HRCT) is used to look closely at the lungs.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials